Biomarin Pharmaceutical Inc. followed up its May takeover of Inozyme Pharma Inc. with a much larger agreement to acquire Amicus Therapeutics Inc. for $14.50 per share in an all-cash transaction, ...

Addition Therapeutics came out of stealth mode to highlight its Precise RNA-Mediated Insertion of Transgenes (PRINT) gene ...

Insilico Medicine Inc. plans to raise HK$2.27 billion (US$292 million) in its IPO on the Hong Kong Securities Exchange to ...

Companion Spine SAS received premarket approval from the U.S. FDA for its DIAM spinal stabilization system, for treatment of ...

Peptidream Inc. has announced progression of an oral dual IL-17A and IL-17F macrocyclic peptide inhibitor for psoriasis, with ...

Med-tech M&A value in 2025 totaled about $38.99 billion through November, reflecting a clear slowdown from 2024’s $57.92 billion and well below the peak years of 2021 and 2022, when 11-month totals ...

Using C-X-C chemokine receptor type 4 (CXCR4) antagonists as cell mobilization agents has resulted in some FDA approved agents, such as Plerixafor, for hematopoietic stem cell transplantation and ...

Nchroma Bio Inc. has received a certificate for clinical trial in Hong Kong to initiate a first-in-human phase I/II trial of ...

Amira Therapeutics SL has announced new preclinical findings for its lead compound AMI-463, which is being developed primarily for rhabdomyosarcoma, the most common soft tissue sarcoma in children.

Biomarin Pharmaceutical Inc. is paying $14.50 per share to acquire rare disease drug developer Amicus Therapeutics Inc. in an all-cash transaction valued at about $4.8 billion. The deal will bolster ...

The Trump administration has made known that it intends to foster rapid adoption of AI, starting with a repeal of an executive order (EO) issued by the Biden administration. Now, the White House has ...

The European Union’s struggles with regulations for devices and in vitro diagnostics seem virtually endless, but the European ...